CTMX Q3 2018 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M-48.2% YoY

Gross Profit

$13M100.0% margin

Operating Income

-$23M-185.3% margin

Net Income

-$23M-187.3% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

-41.4%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$7M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$483M

Total Liabilities

$325M

Stockholders' Equity

$158M

Cash & Equivalents

$260M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$24M	-48.2%
Gross Profit	$13M	$24M	-48.2%
Operating Income	-$23M	-$11M	-110.2%
Net Income	-$23M	-$10M	-128.7%

Revenue Segments

License And Service

$3M100%